
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is experiencing strong growth in new patient starts and an increase in pharmacy adds. They also have a strong sales force expansion and product pipeline, with the potential for FDA approval and launch of their Mint patch pump in 2026, which should help boost revenues and margins. Despite recent headwinds, the company has a solid track record of beating and raising guidance and offers a favorable risk-reward at current levels.
Bears say
Beta Bionics is facing strong competition from both devices, such as Medtronic, Tandem, Insulet, and Sequel, and therapeutics, such as GLP-1s, creating significant pressure on market share and profitability. Additionally, potential risks associated with clinical and regulatory processes for their future products, specifically the Mint patch pump and Bihormonal offerings, could further hinder their ability to gain market traction. These factors, combined with potential market headwinds from CMS proposals and a recent WL from the FDA, may result in downward pressure on BBNX's stock value and delay their commercialization timeline.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares